HIV-1 C4-V3 Polyvalent Peptide Vaccine
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions
HIV Infections
Phase 1
A Phase I Safety and Immunogenicity Trial of HIV-1 gp120 C4-V3 Hybrid Polyvalent Peptide Immunogen Mixed in Mineral Oil Containing Mannose Mono-Oleate (IFA)
CompletedNCT00000886
End: 1999-04-30Updated: 2021-10-29
Safety of the Candidate Vaccine C4-V3 Alone or With Interleukin-12 (IL-12) in HIV-Infected Patients Receiving Effective Anti-HIV Drug Therapy
CompletedNCT00005779
End: 2004-05-31Target: 12Updated: 2021-11-01
A Phase I Trial of HIV-1 C4-V3 Polyvalent Peptide Vaccine in HIV-1 Infected Persons
CompletedNCT00001060
End: 2002-06-30Target: 30Updated: 2013-05-06